Rabeprazole |
Aciphex; rabeprazole sodium |
Article: Rabeprazole
![]() | |
| Rabeprazole | |
| Systematic (IUPAC) name | |
| 2-[(4-(3-methoxypropoxy)- 3-methyl-pyridin-2-yl) methylsulfinyl]- 1H-benzoimidazole | |
| Identifiers | |
| CAS number | 117976-89-3 |
| ATC code | A02BC04 |
| PubChem | 5029 |
| DrugBank | APRD01212 |
| Chemical data | |
| Formula | C18H21N3O3S |
| Mol. weight | 359.444 |
| Pharmacokinetic data | |
| Bioavailability | 52% |
| Metabolism | Hepatic |
| Half life | 1 - 1.5 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
Rabeprazole is a proton pump inhibitor sold (as its sodium salt) under the brand name Aciphex® and Pariet® (distributed by Janssen-Cilag).
It is used in the treatment of gastric ulcers and GERD (or heartburn). It is taken once/day along with a full glass of water (preferable 30 min before breakfast). The duration of treatment is usually 4 weeks but could be longer if the symptoms persist.
Sometimes, one may start feeling better after a few days but it is essential to complete the full course of treatment.
Categories: Proton pump inhibitors | Medical treatment stubs

Not Signed In - 


